new glp 1 drugs GLP-1 analogs, trend in obesity treatment, become even more effective < Pharma < Article List of approved and pending
Description
What Are Exosomes
Glucagon-like peptide-1 and its analogues act in the dorsal raphe and modulate central serotonin to reduce appetite and body weight
The common link is that GLP-1s activate receptors that then work on driving down metabolic risk factors through the following mechanisms: Enhancing glucose dependent insulin secretion Slowing gastric emptying and decreasing appetite Reducing postprandial glucagon and food intake UpToDate 2 : (1) ingestion of food results in (2) release of gastrointestinal peptides (GLP-1 and GIP: glucose-dependent insulinotropic polypeptide, gastric inhibitory peptide) and (3) pancreatic beta cell hormones (insulin and amylin)
Unlike phentermine, every major GLP-1 medication carries FDA approval for long-term use
PMID 12217892
[DOI] [PubMed] [Google Scholar] 4.Malm-Erjeflt M, Bjrnsdottir I, Vanggaard J, et al
